MOH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molina Healthcare Inc (MOH) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with declining net income, EPS, and gross margin. Analysts have consistently downgraded the stock and lowered price targets, citing concerns about guidance and revenue volatility. Technical indicators are neutral, and there are no significant positive catalysts or proprietary trading signals to suggest a strong buying opportunity.
The MACD histogram is positive at 1.648 but contracting, suggesting weakening momentum. RSI is neutral at 48.252, indicating no clear overbought or oversold conditions. Moving averages are converging, reflecting indecision in price direction. Key support is at 143.791, and resistance is at 156.412, with the current pre-market price of 147.2 trading near support levels.
Revenue increased by 8.34% YoY in Q4 2025, showing some top-line growth.
Analysts have downgraded the stock and significantly reduced price targets, citing concerns about Medicaid and Medicare pressure, guidance volatility, and low-margin cyclical business risks. No recent congress trading data or insider buying trends to indicate confidence in the stock.
In Q4 2025, revenue increased to $11.38 billion (up 8.34% YoY), but net income dropped to -$160 million (-163.75% YoY). EPS decreased to -3.16 (-171.17% YoY), and gross margin fell to 10.51% (-23.79% YoY), reflecting significant profitability challenges.
Analysts have downgraded the stock to Neutral or Hold ratings, with price targets lowered significantly (e.g., Morgan Stanley to $128, Wells Fargo to $141, and Deutsche Bank to $109). Analysts cite poor Q4 results, overly optimistic guidance, and revenue/expense volatility as key concerns.
